Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Jun 15;33(6):322–329. doi: 10.1002/clc.20791

Hyponatremia in Heart Failure: Revisiting Pathophysiology and Therapeutic Strategies

Amir Kazory 1,✉
PMCID: PMC6653559  PMID: 20556801

Abstract

Hyponatremia is frequently encountered in patients with heart failure (HF), and its association with adverse outcomes is well‐established in this population. While hyponatremia is an independent marker for severity of HF, it is not certain whether it has a causal impact on the progression of the disease. There are no universally accepted consensus guidelines regarding therapeutic strategies for HF‐associated hyponatremia and volume overload; current societal guidelines do not address management of this complication. Whereas thiazide diuretics are known to induce or worsen hyponatremia in this setting through a number of mechanisms, loop diuretics can be considered a readily available first‐line pharmacologic therapy. Consistent with pathophysiology of the disease and mechanisms of action of loop diuretics, available clinical evidence supports such an approach provided that patients can be closely monitored. Use of vasopressin receptor antagonists is an emerging therapeutic strategy in this setting, and the efficacy of these agents has so far been shown in a number of clinical studies. These agents can be reserved for patients with HF in whom initial appropriate loop diuretic therapy fails to improve serum sodium levels. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (173.6 KB).

References

  • 1. Gheorghiade M, Abraham WT, Albert NM, et al; OPTIMIZE‐HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE‐HF registry. Eur Heart J 2007; 28: 980–988. [DOI] [PubMed] [Google Scholar]
  • 2. Rusinaru D, Buiciuc O, Leborgne L, et al. Relation of serum sodium level to long‐term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol 2009; 103: 405–410. [DOI] [PubMed] [Google Scholar]
  • 3. Yancy CW, Lopatin M, Stevenson LW, et al; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in‐hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76–84. [DOI] [PubMed] [Google Scholar]
  • 4. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581–2587. [DOI] [PubMed] [Google Scholar]
  • 5. Krumholz HM, Chen YT, Bradford WD, et al. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care 1999; 5: 715–723. [PubMed] [Google Scholar]
  • 6. Sica DA. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 2006; 73(suppl 2): S2–S7. [DOI] [PubMed] [Google Scholar]
  • 7. Sun TW, Wang LX. Low levels of B‐type natriuretic peptide predict poor clinical outcomes in patients with chronic and advanced heart failure. Med Hypotheses 2007; 68: 677–679. [DOI] [PubMed] [Google Scholar]
  • 8. Goldsmith SR, Francis GS, Cowley AW Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986; 58: 295–299. [DOI] [PubMed] [Google Scholar]
  • 9. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10–24. [PubMed] [Google Scholar]
  • 10. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic‐induced severe hyponatremia: review and analysis of 129 reported patients. Chest 1993; 103: 601–606. [DOI] [PubMed] [Google Scholar]
  • 11. Sica DA. Hyponatremia and heart failure—treatment considerations. Congest Heart Fail 2006; 12: 55–60. [DOI] [PubMed] [Google Scholar]
  • 12. Sligl W, McAlister FA, Ezekowitz J, et al. Usefulness of spiro‐ nolactone in a specialized heart failure clinic. Am J Cardiol 2004; 94: 443–447. [DOI] [PubMed] [Google Scholar]
  • 13. Padilla MC, Armas‐Hernández MJ, Hernández RH, et al. Update of diuretics in the treatment of hypertension. Am J Ther 2007; 14: 154–160. [DOI] [PubMed] [Google Scholar]
  • 14. Verbalis JG Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120(11): S1–S21. [DOI] [PubMed] [Google Scholar]
  • 15. Ali SS, Olinger CC, Sobotka PA, et al. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail 2009; 15: 1–4. [DOI] [PubMed] [Google Scholar]
  • 16. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1–6. [DOI] [PubMed] [Google Scholar]
  • 17. Issa VS, Bacal F, Mangini S, et al. Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure [in English and Portuguese]. Arq Bras Cardiol 2007; 89: 228–232. [DOI] [PubMed] [Google Scholar]
  • 18. Licata G, Di Pasquale P, Parrinello G, et al. Effects of high‐dose furosemide and small‐volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long‐term effects. Am Heart J 2003; 145: 459–466. [DOI] [PubMed] [Google Scholar]
  • 19. Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007; 23: 21–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Parrinello G, Di Pasquale P, Licata G, et al. Long‐term effects of dietary sodium intake on cytokines and neurohormonal activation in patients with recently compensated congestive heart failure. J Card Fail 2009; 15: 864–873. [DOI] [PubMed] [Google Scholar]
  • 21. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high‐dose furosemide and small‐volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000; 2: 305–313. [DOI] [PubMed] [Google Scholar]
  • 22. Drazner MH, Palmer BF. Hypertonic saline: a novel therapy for advanced heart failure? Am Heart J 2003; 145: 377–379. [DOI] [PubMed] [Google Scholar]
  • 23. Di Pasquale P, Sarullo FM, Paterna S. Novel strategies: challenge loop diuretics and sodium management in heart failure—part I. Congest Heart Fail 2007; 13: 93–98. [DOI] [PubMed] [Google Scholar]
  • 24. Di Pasquale P, Sarullo FM, Paterna S. Novel strategies: challenge loop diuretics and sodium management in heart failure—part II. Congest Heart Fail 2007; 13: 170–176. [DOI] [PubMed] [Google Scholar]
  • 25. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol 2009; 103: 93–102. [DOI] [PubMed] [Google Scholar]
  • 26. Damgaard M, Norsk P, Gustafsson F, et al. Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol 2006; 290: 1294–1301. [DOI] [PubMed] [Google Scholar]
  • 27. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417–2423. [DOI] [PubMed] [Google Scholar]
  • 28. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 2003; 107: 2690–2696. [DOI] [PubMed] [Google Scholar]
  • 29. Gheorghiade M, Gattis WA, O'Conner CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963–1971. [DOI] [PubMed] [Google Scholar]
  • 30. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297: 1319–1331. [DOI] [PubMed] [Google Scholar]
  • 31. Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non‐peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615–1621. [DOI] [PubMed] [Google Scholar]
  • 32. Costello‐Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin‐2‐receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human renal failure. Am J Physiol Renal Physiol 2006; 290: F273–F278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double‐blind, placebo‐controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151–2159. [DOI] [PubMed] [Google Scholar]
  • 34. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2‐receptor antagonist conivaptan in acute decompensated heart failure: a dose‐ranging pilot study. J Card Fail 2008; 14: 641–647. [DOI] [PubMed] [Google Scholar]
  • 35. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J Am Coll Cardiol 2008; 52: 1540–1545. [DOI] [PubMed] [Google Scholar]
  • 36. Schrier RW, Gross P, Gheorghiade M, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099–2112. [DOI] [PubMed] [Google Scholar]
  • 37. Kazory A. Haemodialysis, not ultrafiltration, can correct hyponatraemia in heart failure. Eur J Heart Fail 2010; 12: 208. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES